Merck and Moderna report Phase 3 INTerpath-001 melanoma trial endpoints
Merck and Moderna announce Phase 3 INTerpath-001 results for intismeran autogene plus KEYTRUDA in completely resected Stage IIB-IV melanoma, targeting recurrence-free survival and distant metastasis-free survival endpoints.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.